DM

Showing posts with label Years. Show all posts
Showing posts with label Years. Show all posts

Wednesday, August 14, 2013

JFK Baby Death 50 Years Ago Sparked Race to Save Preemies

Patrick Bouvier Kennedy, born premature, died after 39 hours of life on Aug. 7, 1963, three months before his father, President John F. Kennedy, was assassinated in Dallas.

Though the baby was a healthy weight, he developed what was known then as hyaline membrane disease, a condition that killed about 25,000 children a year. At the time, the first family had Caroline, 5, and John Jr., 2, but Jacqueline Kennedy had previously had a miscarriage and a stillborn daughter.

The death of the presidential baby a half a century ago today was a critical event, according to historians, one that sparked medical advances that did for the survival of preemies what Sputnik did for the space race.

Was the Kennedy assassination an inside job?

That same year, a Canadian doctor had pioneered the controversial use of a ventilator and saved a similarly sick 34-week-old baby, but American doctors couldn't do the same for the Kennedy baby.

"The president was pretty embarrassed about that," said Dr. Jay Greenspan, chief of pediatrics at Thomas Jefferson Medical College and Nemours/A.I. duPont Hospital for Children, where today about 95 percent of all infants diagnosed with what is now known as respiratory distress syndrome survive.

"We have come a long way," said Greenspan. "It was so tragic that the family went though this -- and you wish you could have been there. It was a simple fix. … The baby was really just slightly premature. He would be sort of an afterthought now in the after-care nursery."

Today, respiratory distress syndrome, or RDS, affects more than 16,000 premature infants in the United States each year, according to the March of Dimes. Babies with the condition have immature lungs that lack the protein surfactant that keeps their small air sacs from collapsing.

But it was the presidential spotlight that would ultimately transform the field, giving birth to neonatology and the modern neonatal intensive care unit, or NICU.

Early births can lead to academic problems.

The Kennedy baby's death put a new focus on diseases of the newborn and resulted in increased funding for research by the National Institutes of Health, according to Dr. Suhas M. Nafday, director of Newborn Services at the Children's Hospital at Montefiore Medical Center in New York.

"This event energized the neonatal researchers into action to look for an effective management of RDS," he said.

Millions of babies worldwide have been saved, largely because of the efforts to improve the first infant ventilators and the discovery of surfactant a decade later.

Patrick was born at Otis Air Force Base on Cape Cod at about 37 weeks, weighing 4 pounds, 10? ounces, according to a recent account in The New York Times. As the infant's respiratory distress worsened, he was airlifted to Children's Hospital in Boston, where he was put in a hyperbaric chamber, used mostly for burn victims and divers with the bends or decompression sickness. At the time, Children's was using it for "blue babies," infants born with congenital heart defects that starve their bodies of oxygen and cause a bluish coloration of the skin.

"[Hyperbaric chambers] allowed for a higher oxygen content in their blood, but their lungs were collapsing," said Greenspan.

And oxygen carried risks, such as blindness. Pop singer Stevie Wonder, born six weeks premature, developed retinopathy while in an incubator because of excess oxygen. "We have now learned to control that," he said.

You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.

View the original article here

Friday, June 28, 2013

World's Oldest Human Tumor Discovered - Over 120,000 Years Old

Editor's Choice
Academic Journal
Main Category: Cancer / Oncology
Article Date: 07 Jun 2013 - 0:00 PDT Current ratings for:
World's Oldest Human Tumor Discovered - Over 120,000 Years Old
4 starsnot yet rated
Researchers have just discovered the world’s oldest tumor, in the rib of a 120,000 year old Neanderthal in Croatia.

It is a very rare discovery considering that tumors were uncommon in prehistoric populations. Tumors in fleshy tissue decay quickly - making them difficult to identify.

Spelling: both "Neandertals" and "Neandertals" are correct.

The bone was originally excavated a hundred years ago and scientists have just found out that the it has a cavity, where a tumor, known as fibrous dysplasia, replaced what should have been inner bone structure.

Fibrous dysplasia is not considered to be cancerous, because the tumors do not spread to other tissues.

According to David Frayer, professor of anthropology at the University of Kansas, and co-author of the paper:

"It's evidence that Neanderthals suffered tumors - that they were susceptible to the same kinds of diseases that we see in modern humans. Before this, the earliest tumor in bone that we've seen goes back to an Egyptian mummy. So this is 100,000 years older than the previous tumor that has been found. There is no evidence of cancer older than this in the human fossil record."

The 30-millimeter-long left rib fragment was unearthed between 1899 and 1905 in a Croatian cave that contained around 900 Neanderthal bones - hundreds of thousands of years old.

Back in the 1980s, all the bones from the cave were x-rayed and published in a book which showed each radiogram, with the exception of the rig fragment - which appeared burned out in the x-ray image.

Finally, using new high quality X-rays, researchers have been able to look at the bone more clearly.

They found that the rib contained a cavity 18 millimeters in length and 7.6 millimeters wide. After thorough analysis with radiograph and CT scans, the scientists concluded that the cavity was the site of a benign tumor associated with Fibrous dysplasia, which "is a developmental disorder of bone in which lesions develop fibrous tissue and spicules of woven bone."

Frayer said:

"It wasn't a small tumor. It was a fairly large one, probably bulging at the base of the rib. We're not sure how far along it was, but it was well-expressed in the bone. It was in the upper third of the back, and muscles attach there that are associated with raising the arm."

Frayer also mentioned that there may have been other bones involved, but they have not been identified. Adding that, although the site contained more than 900 bones "very few of them are associated one with the other. And while there are other pathologies, none of the others show evidence of a tumor."

Neanderthaler Fund

Neanderthals are more similar to modern day humans than previously thought.

Scientists were once sure that Neanderthals had no influence on the evolutionary line of modern day humans., However, although Neanderthals died out 30,000 years ago and were a different species of human compared to modern day homo sapiens, we share much of the same DNA.

Frayer concluded:

"We have actual nuclear DNA from a number of different Neanderthals - not complete sequences - but segments of nuclear DNA. So we know that Neanderthals have a set of unique genes that were passed on to modern humans. It's about 4 percent of our genetic makeup."

By analyzing DNA extracted from three Neanderthal bones over 40,000 years old, European and the US researchers revealed that some Neanderthal DNA were passed on to humans.

Written by Joseph Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our cancer / oncology section for the latest news on this subject. "Fibrous Dysplasia in a 120,000+ Year Old Neandertal from Krapina, Croatia"
Janet Monge, Morrie Kricun, Jakov Radov?i?, Davorka Radov?i?, Alan Mann, David W. Frayer
PLoS ONE Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Nordqvist, Joseph. "World's Oldest Human Tumor Discovered - Over 120,000 Years Old." Medical News Today. MediLexicon, Intl., 7 Jun. 2013. Web.
11 Jun. 2013. APA

Please note: If no author information is provided, the source is cited instead.



'World's Oldest Human Tumor Discovered - Over 120,000 Years Old'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Thursday, June 20, 2013

60 Years Of Data Suggest A Link Between Obesity And Height In Childhood And Endometrial Cancer In Adulthood

Main Category: Obesity / Weight Loss / Fitness
Also Included In: Cancer / Oncology
Article Date: 14 May 2013 - 1:00 PDT Current ratings for:
60 Years Of Data Suggest A Link Between Obesity And Height In Childhood And Endometrial Cancer In Adulthood
not yet ratednot yet rated
New research presented at the European Congress in Liverpool (ECO) beginning today (Sunday 12 May) shows a possible link between obesity and height in childhood and endometrial cancer in adulthood. The research* is by Julie Aarestrup, Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark, and colleagues.

Endometrial cancer is in Europe the fourth most common cancer in women with more than 90,000 new cases diagnosed each year. In adult women, a high body mass index (BMI) is associated with an increased risk of endometrial cancer, whereas associations with height are limited. It is largely unknown, however, whether any of the risk originates in childhood. In this new study, the researchers investigated if childhood BMI and height at each age from 7-13 years were associated with risk of endometrial cancer in adulthood.

The total cohort consisted of 158,459 women from the Copenhagen School Health Records Register with data on measured heights and weights at 7-13 years who were born from between 1930 and 1989. BMI and height were transformed into age-specific z-scores, a method for comparing how large or tall a child is compared to a reference population. Follow-up occurred by linkage via a personal identification number to the Danish Cancer Registry, the Hospital Discharge Register (hysterectomy information), and the vital statistics register. Subjects were followed until a diagnosis of endometrial cancer, hysterectomy, death, emigration, loss-to-follow-up, or December 31, 2010; whichever came first.

The researchers found 940 diagnoses of endometrial cancer occurred during follow-up. At age 7 the risk of endometrial cancer in adulthood increased 18% per increase in BMI z-score and by 12% per increase in height z-score. To put this in perspective, compared to an average height and weight girl born in the late 1950s (122.4 cm, 22.9kg), another girl of the same height but who weighed 3.3 kg more would have an 18% higher risk of endometrial cancer. Further, height also increased the risk; compared to the same average girl, another girl of the same age but who was 5.2cm taller had a 12% increased risk of endometrial cancer. When looking at a girl aged 13 years born in the late 1950s compared to an average height and weight girl (156.7cm, 44.6 kg), another girl of the same height but who weighed 6.8kg more had a 24% increased risk of endometrial cancer; and another girl of the same age but who was 6.9cm taller had a 15% increased risk of endometrial cancer.

The peak age of endometrial cancer diagnosis is approximately 65 years. Therefore girls born in the 1950s are approaching their highest risk years. As the cohort members from later birth years continue to age, the study will continue to follow them in order to assess their risk of endometrial cancer.

Aarestrup concludes: "Higher BMI and height during childhood are associated with an increased risk of endometrial cancer in adulthood. These results suggest that some risk of endometrial cancer observed in adult women has its origins in childhood."

Research is ongoing to refine these results by subtypes of endometrial cancer. This project forms part of a series of studies led by Dr. Jennifer L. Baker, also of the Institute of Preventive Medicine, that are exploring associations between childhood body size and the later risk of cancers including those of the liver, prostate and thyroid. *This study is part of the European Research Council (ERC) project 'Childgrowth2cancer: Childhood body size, growth and pubertal timing and the risk of cancer in adulthood' which is run by Associate Professor Jennifer L. Baker.

Article adapted by Medical News Today from original press release. Source: Source: European Congress on Obesity (ECO)
Visit our obesity / weight loss / fitness section for the latest news on this subject. Source: European Congress on Obesity (ECO) Please use one of the following formats to cite this article in your essay, paper or report:

MLA

ECO. "60 Years Of Data Suggest A Link Between Obesity And Height In Childhood And Endometrial Cancer In Adulthood." Medical News Today. MediLexicon, Intl., 14 May. 2013. Web.
20 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'60 Years Of Data Suggest A Link Between Obesity And Height In Childhood And Endometrial Cancer In Adulthood'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, June 18, 2013

10 Years On Tamoxifen Halves Breast Cancer Recurrence Risk

Editor's Choice
Main Category: Breast Cancer
Also Included In: Cancer / Oncology
Article Date: 03 Jun 2013 - 4:00 PDT
Current ratings for:
10 Years On Tamoxifen Halves Breast Cancer Recurrence Risk
5 starsnot yet rated
Survivors who take tamoxifen for ten years have half the risk of dying from estrogen receptor positive breast cancer, researchers from Cancer Research UK reported at the ASCO Annual Meeting in Chicago, Illinois, USA.

Lead researcher, Dr Daniel Rea reported that the "aTTom" study demonstrated that estrogen receptor positive breast cancer patients who took tamoxifen for longer than five years were much less likely to suffer cancer recurrence or die from the disease. Currently, the recommended period for tamoxifen therapy is five years.

The study involved 6,953 adult females with breast cancer. 580 patients from 3,468 women took tamoxifen for ten years, while 672 of 3,485 patients stopped tamoxifen after five years.

Dr Rea reported that: 25% of the 10-year tamoxifen patients had fewer recurrences of breast cancer than those on just five years of therapyThere were 23% fewer deaths in the 10-year tamoxifen groupDr Daniel Rea, who is based at the University of Birmingham, England, said:

"These results are important as they establish that giving tamoxifen for longer than the current standard of five years significantly cuts the risk of breast cancer returning.

Doctors are now likely to recommend continuing tamoxifen for an extra five years and this will result in many fewer breast cancer recurrences and breast cancer deaths worldwide. Tamoxifen is cheap and widely available so this could have an immediate impact."

Approximately three-quarters of all breast cancers are of the estrogen receptor positive kind. This type of breast cancer benefits from hormone therapy. Estrogen, a female hormone, encourages breast cancers to grow by activating estrogen receptors. Tamoxifen works by blocking these receptors, thus making it much harder for the cancer to recur after surgery or invade the other breast.

Tamoxifen side effects - patients on tamoxifen may experience menopausal-type symptoms, including hot flashes (UK: hot flushes) and night sweats. A Norwegian study found that acupuncture reduces menopausal symptoms in tamoxifen patients by 50%. More rarely, tamoxifen has also been linked to an increased risk of developing blood clots, endometrial cancer and stroke.

Stroke risk did not rise with 10 years of tamoxifen therapy compared to five years, the researchers found. However, the risk of endometrial cancer did increase. Fortunately, endometrial cancer is usually diagnosed in the early stages of the disease, when it can be treated successfully.

According to the researchers, thirty breast cancer deaths would be prevented for every endometrial cancer death due to long-term tamoxifen therapy.

Professor Richard Gray, who is based at the University of Oxford and was also presenting the aTTom trial results at ASCO, said:

"Five years of tamoxifen is already an excellent treatment but there have been concerns that giving it for longer might not produce extra benefits and could even be harmful. The aTTom study establishes that the benefits of taking tamoxifen for longer greatly outweigh the risks.

Kate Law, director of clinical research at Cancer Research UK, said: "Large clinical trials like aTTom are vitally important to understand how drugs such as tamoxifen work and how best to use them. We need these sorts of studies so we can be sure the benefits from cancer drugs outweigh the side-effects that they may have."

The aTTom trial was funded by the Medical Research Council, UK.

A trial led by Oxford University's Clinical Trial Service Unit reported in The Lancet (December 2012 issue) that taking tamoxifen for ten years after breast cancer surgery is more effective than five years. The study was called ATLAS.

Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our breast cancer section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Nordqvist, Christian. "10 Years On Tamoxifen Halves Breast Cancer Recurrence Risk." Medical News Today. MediLexicon, Intl., 3 Jun. 2013. Web.
5 Jun. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'10 Years On Tamoxifen Halves Breast Cancer Recurrence Risk'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here